Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Heart failure

SGLT-2 inhibitors reduce heart failure risk across patient groups

Data show the risk of heart failure was 34% lower in patients taking SGLT-2 inhibitors, compared with those taking DPP-4 inhibitors

Heart x-ray

Source: Shutterstock.com

Data show the risk of heart failure was 34% lower in patients taking SGLT-2 inhibitors, compared with those taking DPP-4 inhibitors

Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are associated with a reduced risk of heart failure compared with dipeptidyl peptidase 4 (DPP-4) inhibitors, even in people without a history of cardiovascular disease, a study published in The BMJ has shown (29 August 2019)[1].

Researchers compared 20,983 new users of SGLT-2 inhibitors matched to an equal number of new DPP-4 inhibitor users from Scandinavian nationwide databases from April 2013 to December 2016.

Overall, 19% of patients across both groups had a history of major cardiovascular disease.

During median follow-up of 1.4 years, the risk of heart failure was 34% lower in patients taking SGLT-2 inhibitors, but there was no difference between groups in the risk of major cardiovascular events (composite outcome of myocardial infarction, stroke and cardiovascular death) or for either of these outcomes individually.

SGLT-2 inhibitors were also associated with a 20% reduction in all-cause mortality.

Previous research has shown that SGLT-2 inhibitors reduce the risk of major cardiovascular events and heart failure in people with cardiovascular disease or at high cardiovascular risk, the team explained in The BMJ.

“Patients with such histories are likely to derive the largest absolute benefit,” the team wrote.

However, they say that their evidence supported “the notion that SGLT2 inhibitors could reduce risk of heart failure outcomes in a broad group of patients at varying levels of cardiovascular risk”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207188

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.